Key takeaways
- • Frequency: Common — 5-11% in trials.
- • Trial reference: STEP-1 (semaglutide) (5-11%).
- • Management: typically resolves within 4-8 weeks as the body adapts.
- • When to call doctor: see red-flag list below.
Why this happens
Reduced food intake during early treatment can cause low blood sugar in non-diabetics and energy deficit. Once stable at therapeutic dose, fatigue usually resolves.
How to manage it
- Hit protein target (1.2-1.6g/kg body weight per day) — protein deficiency drives fatigue more than calorie deficit
- Electrolytes — sodium, magnesium, potassium often drop on rapid weight loss
- Sleep 7+ hours; poor sleep amplifies all fatigue
- Light activity (walking) often helps more than rest
- Check thyroid + iron panels if fatigue persists past month 3
GLP1Zoom doesn't prescribe — these are general management guidance from FDA labels and clinical trial reports. Personalized recommendations require your prescribing clinician.
When to call your doctor
Red flags — seek medical attention
- • Fatigue + significant weight loss faster than 2 lbs/week (over-restriction)
- • Fatigue + signs of hypoglycemia (sweating, confusion, rapid heart rate)
- • Persistent fatigue beyond month 3 — warrants blood work
Drug-specific notes
- Wegovy: Fatigue ~11% in STEP-1 trial
- Saxenda: Fatigue ~7% in SCALE trial
Other GLP-1 symptoms
Gastrointestinal
Nausea on GLP-1 medications
Gastrointestinal
Diarrhea on GLP-1 medications
Gastrointestinal
Constipation on GLP-1 medications
Neurological
Headache on GLP-1 medications
Skin / Hair
Hair loss on GLP-1 medications
Gastrointestinal
Gallbladder issues on GLP-1 medications
Symptom management is general guidance based on FDA-approved prescribing information. Always discuss specifics with your prescribing clinician. In medical emergencies, call 911 or go to the nearest emergency department. Full disclaimer.
References
Endocrine Society Clinical Practice Guideline: Pharmacological Management of Obesity(2015)
STEP-1 trial: Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding et al., NEJM)(2021)
SURMOUNT-1 trial: Tirzepatide Once Weekly для Treatment of Obesity (Jastreboff et al., NEJM)(2022)
Glucagon-Like Peptide-1 Receptor Agonists: Mechanisms и Clinical Use (Drucker, Cell Metabolism)(2018)
Tirzepatide GIP/GLP-1 Dual Agonism: Mechanism Review (Lancet Diabetes & Endocrinology)(2021)
GLP-1 Effects on Gastric Emptying: Pharmacology Review (American J Physiology)(2020)
SUSTAIN-6 trial: Semaglutide and Cardiovascular Outcomes (Marso et al., NEJM)(2016)
SURPASS-2 trial: Tirzepatide vs Semaglutide в Type 2 Diabetes (Frias et al., NEJM)(2021)
LEADER trial: Liraglutide and Cardiovascular Outcomes в T2D (Marso et al., NEJM)(2016)